title: Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
abstract: BACKGROUND
  While the benefit of passive immunotherapy is commonly accepted, active immunization may have advantages for the patient's quality of life. We identified a new epitope of Mab CH401 against Her-2/neu extracellular domain (N: 167-175), and evaluated the effect of active immunization of the 20mer peptide containing the epitope (CH401 peptide).
  
  
  METHODS
  Epitope-mapping was performed using ELISA with Her-2/neu-related multiple antigen peptides (MAP). BALB/c mice were transplanted with Her-2/neu-expressing lymphoma cell line and immunized with the peptides. For monitoring the condition, ELISA and flow cytometry was performed.
  
  
  RESULTS
  CH401 peptide induced Her-2/neu-specific IgG antibody. Tumor growth in immunized mice was suppressed and tumor-infiltrating lymphocytes comprised more CD8(+) T-cells, which secreted larger amounts of interleukin-2 after the peptide re-stimulation.
  
  
  CONCLUSIONS
  The new Her-2/neu peptide contained epitopes for CD4(+) and CD8(+) T-cells, which contributes to the suppressive effect on Her-2/neu-expressing tumor cell growth.
authors.affiliation: Department of Surgery, Tokai University School of Medicine, Kanagawa, Japan.
authors.forename: Hirohito
authors.initials: H
authors.lastname: Miyako
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Kametani
authors.forename: Ikumi
authors.initials: I
authors.lastname: Katano
authors.forename: Ryoji
authors.initials: R
authors.lastname: Ito
authors.forename: Banri
authors.initials: B
authors.lastname: Tsuda
authors.forename: Atsuko
authors.initials: A
authors.lastname: Furukawa
authors.forename: Yuki
authors.initials: Y
authors.lastname: Saito
authors.forename: Dai
authors.initials: D
authors.lastname: Ishikawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Ogino
authors.forename: Shigeru
authors.initials: S
authors.lastname: Sasaki
authors.forename: Kohzoh
authors.initials: K
authors.lastname: Imai
authors.forename: Sonoko
authors.initials: S
authors.lastname: Habu
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Makuuchi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tokuda
mesh_terms: D020816:Amino Acid Motifs; D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018604:Epitope Mapping; D018985:Epitopes, B-Lymphocyte / Q000737:chemistry / Q000276:immunology*; D005260:Female; D006801:Humans; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009368:Neoplasm Transplantation; D010455:Peptides / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000276:immunology*; D014611:Vaccination
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D018985:Epitopes, B-Lymphocyte; D010455:Peptides; D018719:Erb-b2 Receptor Tyrosine Kinases